Another experimental Alzheimer's drug can modestly slow patients' inevitable worsening — by about four to seven months, researchers reported Monday.
WASHINGTON, D.C. -- Another experimental Alzheimer's drug can modestly slow patients' inevitable worsening — by about four to seven months, researchers reported Monday.
"We don't cure the disease," he said."Diabetes doesn't have a cure either — it doesn't mean you can't have very meaningful treatments for patients." Scientists say while these drugs may mark a new era in Alzheimer's therapy, huge questions remain about which patients should try them and how much benefit they'll really notice.
The study had a few twists. Patients were switched to dummy infusions if enough amyloid cleared out — something that happened to about half within a year. And because amyloid alone doesn't cause Alzheimer's, researchers also tracked levels of another culprit in the brain — abnormal tau. More tau signals more advanced disease.
Another way of measuring: Among the donanemab recipients with lower tau levels, 47% were considered stable a year into the study compared with 29% of those who got the dummy version. Widera noted that the possibility of stopping donanemab treatment at least temporarily in people who respond well would help limit some of those challenges. For comparison, Leqembi is given by IV every two weeks and researchers didn't test a similar stoppage.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Second Alzheimer's drug in the pipeline promises to slow worsening but with safety concernAnother experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, according to a study of 1,700 patients. Eli Lilly and Co. is seeking Food and Drug Administration approval of donanemab.
Read more »
Groundbreaking new Alzheimer's drug promises to slow the diseaseThe FDA has approved a groundbreaking new Alzheimer’s drug that promises to slow the disease for patients. NBC10’s Randy Gyllenhaal has more on the benefits and the risks that patients should discuss with their doctors.
Read more »
Groundbreaking Alzheimer’s drug slows disease: A ‘new era’ for treatmentDonanemab has been linked to a 40% lower risk of progressing from mild cognitive impairment to mild dementia.
Read more »
Second Alzheimer's drug in pipeline can slow the disease by a few months but with safety riskNew research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening.
Read more »
Kimiko Glenn Says Orange Is the New Black Actors Needed Second JobsHer TikTok echoed sentiments Sean Gunn had on Netflix’s picket line Friday.
Read more »